Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

PURPOSE: To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). METHODS: Patients with aRCC wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703447/
https://www.ncbi.nlm.nih.gov/pubmed/33246931
http://dx.doi.org/10.1136/esmoopen-2020-001079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703447/
https://www.ncbi.nlm.nih.gov/pubmed/33246931
http://dx.doi.org/10.1136/esmoopen-2020-001079

Ejemplares similares